![IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/IHB_Pharmacy_By_Theihb_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
company published solid first quarter of 2023 financial report, where Revenue grew by 5.397 % to $
62.85 billions relative to $59.63 billions on a year-over-year basis, ABC recorded earnings advance of 9.39 % to $2.33, as relative to at $2.13 in the prior year financial reporting period.
Revenues surged by 2.734 % from $61.17 billions in preceding period, Income per Share soared by 68.2 % from $1.39 per share.
Earnings of $476.170 millions in the fiscal span closing December 31 2022 increased by 5.95 % from net earnings of $449.416 millions reported in the fiscal span closing December 31 2022 a year ago. Although operating margin fell to 1.01%, in the fiscal span closing December 31 2022, the Amerisourcebergen Corps' net margin actually improved to 0.76%.
Operating earnings, fell -1.75% to $633.143 millions, squeezing Amerisourcebergen Corp's operating margin to 1.01%, from 1.08% in the first quarter of 2022.
Amerisourcebergen Corp is expected to report next financial earnings on May 03, 2023.